💉A Vaccine Designed by a Machine, Tested in Humans

For the first time, a vaccine whose active ingredient was designed entirely by artificial intelligence — not just assisted by it — has passed its first human trial. It targets every known coronavirus at once, including strains that do not yet exist.

Every time a new variant of COVID-19 emerged, vaccine makers faced the same race: identify the mutation, redesign the shot, manufacture it, distribute it. The virus would move; the vaccine would follow — always slightly behind. It was, in a sense, like trying to update a map of a city that kept rearranging its streets.

What if the vaccine didn't target one variant at all, but targeted the thing that every coronavirus shares, no matter how much it mutates?

That is the question researchers at the University of Cambridge and their spin-out company DIOSynVax set out to answer. And in June 2026, they published results showing the approach works in humans.

How the AI Designed It

Traditional vaccines are built around an antigen — a fragment of a specific virus that trains the immune system to recognise it. The problem is specificity: a shot designed against one strain may not protect against another.

The Cambridge team used machine learning to analyse global genetic sequence data from the entire Sarbecovirus group — the large family of coronaviruses that includes SARS-CoV-1, SARS-CoV-2 (which caused COVID-19), MERS, and dozens of bat coronaviruses that have not yet made the jump to humans. The AI searched for the structural features shared across the whole family — a kind of molecular fingerprint that cannot easily mutate away without the virus losing its ability to function.

It then designed a "super-antigen": a synthetic protein that exposes these conserved features to the immune system, training it to recognise not just one coronavirus, but all of them.

The Trial

The Phase 1 trial, published in the Journal of Infection (June 2026), enrolled 39 healthy adult volunteers. The vaccine was delivered without a needle — using a microfluid jet device that presses the liquid through the skin. It showed no serious side effects and triggered immune responses not just against SARS-CoV-2 and SARS, but against related bat viruses — potential future pandemic threats that have not yet infected a single human.

A larger Phase 2 trial is planned to test how broadly and durably protective these responses are.

This is not a ready vaccine. It is a proof that the approach works. But what it points toward is significant: the possibility of a one-time shot that prepares the immune system for a whole category of viruses — including ones evolution has not yet produced.

CITATION: ScienceDaily / University of Cambridge — https://www.sciencedaily.com/releases/2026/06/260605023357.htm Journal of Infection paper — https://doi.org/10.1016/j.jinf.2026.106759